arrow
C

Colleen F. Kelley

Emory University
H指数:38
被引数:8,185

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Viral variant but not host factors associate with SARS-CoV-2 viral kinetics

病毒变体而非宿主因素与SARS-CoV-2病毒动力学相关联

2026-04-170
OAAI
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial

安全性、药代动力学及中和活性研究:PGDM1400LS(一种特异性靶向HIV-1的广谱中和抗体)在美国HIV-1阴性人群中经静脉或皮下输注的评估(HVTN 140/HPTN 101部分A):一项首次人体、1期随机试验

2025-05-270
PRE
Policy Recommendations to Support Equitable Access to Long-Acting Injectables for Human Immunodeficiency Virus Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association
2025-01-280
PRE
HVTN 123: A Phase 1, Randomized Trial Comparing Safety and Immunogenicity of CH505TF gp120 Produced by Stably and Transiently Transfected Cell Lines
2024-12-130
PRE
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
2024-11-272
PRE
Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial

在COVE试验的开放标签阶段,年龄和给药间隔对Delta和Omicron新型冠状病毒肺炎发病率的影响

2024-11-250
OA
Impact of doxycycline post-exposure prophylaxis for sexually transmitted infections on the gut microbiome and antimicrobial resistome

多西环素暴露后预防性传播感染对肠道微生物组和抗菌药物耐药组的影响

2024-10-030
OAAI
Oral Preexposure Prophylaxis Uptake and Discontinuation in the HIV Vaccine Trials Network 704/HIV Prevention Trials Network 085 Study: Implications for Biomedical Human Immunodeficiency Virus Prevention Trials
2024-07-160
OAAI
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV
2024-04-273
OAAI
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials
2024-03-293
OAAI
Prevalence of SARS-CoV-2 Infection among Children and Adults in 15 US Communities, 2021
2024-02-011
OAAI
Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In Vivo
2023-11-292
PRE